Migraine-specific medicines for migraine patients appear to be on the horizon.
Migraine is the most common cause of disability due to a neurological problem in the world (Lancet 2015; 386:743), so when a new treatment comes along, it is worth a second look. Migraine-prevention treatments are currently a rag-tag collection of other disease hand-me-downs with impressive side-effect credentials, a testimony to the disabling nature of the problem since patients and doctors alike accept them.
These authors present two phase II randomized, parallel-group, placebo-controlled, manufacturer-funded trials in migraine prevention: one for episodic migraine (EM), the other for chronic migraine (CM). The active treatment was a calcitonin gene-related peptide (CGRP) humanized monoclonal TEV-48125 (Tev-Mab). In the EM study, 297 patie…
Reviewing Author
DisclosuresConsultant/Advisory BoardAeon Biopharma; Allergan/Abbvie; CoolTech LLC; Dr Reddys; Eli Lilly and Company, Epalex; Lundbeck; Novartis; Pfizer; Praxis; Sanofi; Teva Pharmaceuticals and Tremeau; Gerson Lehrman Group; Guidepoint; Massachusetts Medical Society; Vector Metric; UptoDate
RoyaltiesOxford University Press; Wolters Kluwer
Grant/Research SupportCelgene
Leadership Positions in Professional SocietiesAmerican Headache Society (Immediate Past President)
OtherPatent on magnetic stimulation for headache assigned to eNeura without fee
DisclosuresConsultant/Advisory BoardAeon Biopharma; Allergan/Abbvie; CoolTech LLC; Dr Reddys; Eli Lilly and Company, Epalex; Lundbeck; Novartis; Pfizer; Praxis; Sanofi; Teva Pharmaceuticals and Tremeau; Gerson Lehrman Group; Guidepoint; Massachusetts Medical Society; Vector Metric; UptoDate
RoyaltiesOxford University Press; Wolters Kluwer
Grant/Research SupportCelgene
Leadership Positions in Professional SocietiesAmerican Headache Society (Immediate Past President)
OtherPatent on magnetic stimulation for headache assigned to eNeura without fee